Shmuel Shoham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1089664/publications.pdf

Version: 2024-02-01

99 papers 9,149 citations

76326 40 h-index 90 g-index

106 all docs

106
docs citations

106 times ranked 13494 citing authors

#	Article	IF	Citations
1	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	5.8	1,429
2	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, , .	5.8	708
3	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	13.7	695
4	Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020, 130, 2757-2765.	8.2	649
5	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. Journal of Clinical Investigation, 2020, 130, 6141-6150.	8.2	375
6	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infectious Diseases, The, 2010, 10, 521-526.	9.1	329
7	The immune response to fungal infections. British Journal of Haematology, 2005, 129, 569-582.	2.5	327
8	Toll-Like Receptor 4 Mediates Intracellular Signaling Without TNF-α Release in Response to <i>Cryptococcus neoformans</i> Polysaccharide Capsule. Journal of Immunology, 2001, 166, 4620-4626.	0.8	301
9	Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 882-913.	4.9	293
10	The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts. Clinical Infectious Diseases, 2014, 58, 214-224.	5.8	197
11	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. New England Journal of Medicine, 2022, 386, 1700-1711.	27.0	194
12	Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen Cryptococcus neoformans In Vivo. Infection and Immunity, 2004, 72, 5373-5382.	2.2	173
13	Acute Bacterial Suppurative Thyroiditis: A Clinical Review and Expert Opinion. Thyroid, 2010, 20, 247-255.	4.5	173
14	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. Journal of Clinical Microbiology, 2021, 59, .	3.9	170
15	Invasive fungal infections in solid organ transplant recipients. Future Microbiology, 2012, 7, 639-655.	2.0	142
16	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. Clinical Infectious Diseases, 2014, 58, 1219-1226.	5.8	142
17	Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen Interaction. Journal of Clinical Microbiology, 2004, 42, 4744-4748.	3.9	138

#	Article	IF	CITATIONS
19	Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation, 2016, 100, e74-e80.	1.0	120
20	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clinical Infectious Diseases, 2021, 72, S121-S127.	5.8	109
21	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet, The, 2021, 397, 562-564.	13.7	105
22	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses, 2011, 54, 46-51.	4.0	98
23	Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Therapeutics and Clinical Risk Management, 2008, Volume 4, 637-640.	2.0	97
24	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. Journal of Infectious Diseases, 2020, 222, 1974-1984.	4.0	96
25	Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respiratory Medicine, the, 2017, 5, 500-511.	10.7	85
26	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine, the, 2019, 7, 941-950.	10.7	83
27	Operation Warp Speed: implications for global vaccine security. The Lancet Global Health, 2021, 9, e1017-e1021.	6.3	72
28	Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Medical Mycology, 2010, 48, 511-517.	0.7	68
29	Cryptococcus neoformans Meningitis at 2 Hospitals in Washington, D.C.: Adherence of Health Care Providers to Published Practice Guidelines for the Management of Cryptococcal Disease. Clinical Infectious Diseases, 2005, 40, 477-479.	5.8	66
30	Correcting COVID-19 vaccine misinformation. EClinicalMedicine, 2021, 33, 100780.	7.1	63
31	Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 1897-1906.	3.2	59
32	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	8.2	58
33	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. MBio, 2021, 12, .	4.1	57
34	Pneumocystis pneumonia in children. Paediatric Respiratory Reviews, 2009, 10, 192-198.	1.8	54
35	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. Journal of Antimicrobial Chemotherapy, 2019, 74, 3056-3062.	3.0	54
36	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	2.6	50

#	Article	IF	Citations
37	Emerging fungal infections in solid organ transplant recipients: Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13525.	1.6	49
38	Invasive Fungal Infections in the ICU. Journal of Intensive Care Medicine, 2010, 25, 78-92.	2.8	46
39	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine, 2021, 39, 101053.	7.1	45
40	A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. Clinical Infectious Diseases, 2020, 71, 2787-2795.	5.8	44
41	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. Open Forum Infectious Diseases, 2017, 4, ofx200.	0.9	43
42	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Advances, 2022, 6, 3678-3683.	5.2	42
43	Clinical characteristics and outcomes of invasive <i>Lomentospora prolificans</i> infections: Analysis of patients in the FungiScope [®] registry. Mycoses, 2020, 63, 437-442.	4.0	41
44	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 2021, 8, ofaa574.	0.9	41
45	Emerging Fungal Infections in Solid Organ Transplant Recipients. Infectious Disease Clinics of North America, 2013, 27, 305-316.	5.1	38
46	The silent and dangerous inequity around access to COVID-19 testing: A call to action. EClinicalMedicine, 2022, 43, 101230.	7.1	33
47	Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. Journal of Infection, 2005, 51, e249-e251.	3.3	32
48	Total Penis, Scrotum, and Lower Abdominal Wall Transplantation. New England Journal of Medicine, 2019, 381, 1876-1878.	27.0	31
49	Impact of Multidrug-Resistant Organisms on Patients Considered for Lung Transplantation. Infectious Disease Clinics of North America, 2013, 27, 343-358.	5.1	30
50	Candidemia in Patients with Ventricular Assist Devices. Clinical Infectious Diseases, 2007, 44, e9-e12.	5.8	29
51	Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. Journal of Clinical Virology, 2021, 145, 104997.	3.1	28
52	The pharmacology and clinical use of caspofungin. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 263-274.	3.3	26
53	Pulmonary Zygomycosis. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 111-120.	2.1	26
54	Management of Indwelling Tunneled Pleural Catheters. Chest, 2020, 158, 2221-2228.	0.8	25

#	Article	IF	CITATIONS
55	ABO blood group and SARSâ€CoVâ€2 antibody response in a convalescent donor population. Vox Sanguinis, 2021, 116, 766-773.	1.5	22
56	High Proportion of Indeterminate Qua.jpegERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps. Open Forum Infectious Diseases, 2014, 1, ofu088.	0.9	18
57	Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis?. Mycoses, 2019, 62, 413-417.	4.0	18
58	Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transplant Infectious Disease, 2021, 23, e13521.	1.7	18
59	The Assessment of Convalescent Plasma Efficacy against COVID-19. Med, 2020, 1, 66-77.	4.4	17
60	Cardiac assist device infections. Current Infectious Disease Reports, 2009, 11, 268-273.	3.0	16
61	Transplant of SARS-CoV-2–infected Living Donor Liver: Case Report. Transplantation Direct, 2021, 7, e721.	1.6	16
62	Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. Clinical Infectious Diseases, 2022, 74, 1691-1695.	5.8	16
63	Effects of Immunomodulatory and Organism-Associated Molecules on the Permeability of an <i>In Vitro</i> Blood-Brain Barrier Model to Amphotericin B and Fluconazole. Antimicrobial Agents and Chemotherapy, 2010, 54, 1305-1310.	3.2	15
64	Cryptococcus neoformans Prosthetic Joint Infection: Case Report and Review of the Literature. Mycopathologia, 2015, 179, 275-278.	3.1	15
65	Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2938-2944.	3.0	15
66	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. Transplantation Direct, 2022, 8, e1268.	1.6	14
67	How do I implement an outpatient program for the administration of convalescent plasma for <scp>COVID</scp> ‶9?. Transfusion, 2022, , .	1.6	13
68	Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children. JCI Insight, 2022, 7, .	5.0	12
69	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	5.0	12
70	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	4.7	11
71	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine, 2021, 36, 100925.	7.1	11
72	Early serum (1→3)â€Î²â€Dâ€glucan levels in patients with burn injury. Mycoses, 2012, 55, 224-227.	4.0	10

#	Article	IF	CITATIONS
73	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 493-500.	5.8	10
74	Quantifying infection risks in incompatible living donor kidney transplant recipients. American Journal of Transplantation, 2021, 21, 1564-1575.	4.7	9
75	Association Between Blood Glucose Levels and Development of Candidemia in Hospitalized Patients. Endocrine Practice, 2009, 15, 111-115.	2.1	8
76	Graded isavuconazole introduction in a patient with voriconazole allergy. Transplant Infectious Disease, 2017, 19, e12772.	1.7	8
77	Single Academic Center Experience of Unrestricted \hat{I}^2 -d-Glucan Implementation. Open Forum Infectious Diseases, 2018, 5, ofy195.	0.9	8
78	Urgent needs to accelerate the race for COVID-19 therapeutics. EClinicalMedicine, 2021, 36, 100911.	7.1	7
79	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. PLoS Medicine, 2021, 18, e1003772.	8.4	7
80	Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals. Journal of Antimicrobial Chemotherapy, 2020, 75, 221-228.	3.0	6
81	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. BMC Immunology, 2022, 23, 7.	2.2	6
82	Angioinvasive, cutaneous infection due toColletotrichum siamensein a stem cell transplant recipient: Report and review of prior cases. Transplant Infectious Disease, 2019, 21, e13153.	1.7	5
83	Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis. Diagnostic Microbiology and Infectious Disease, 2012, 73, 374-375.	1.8	4
84	Host/Pathogen Interactions in Fungal Keratitis. Current Fungal Infection Reports, 2015, 9, 52-56.	2.6	4
85	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
86	Treatment of latrogenic Fungal Infections: A Black Mold Defines a New Gray Zone in Medicine. Annals of Internal Medicine, 2013, 158, 208.	3.9	3
87	Antimicrobial Access in the 21st Century: Delays and Critical Shortages. Annals of Internal Medicine, 2016, 165, 53.	3.9	3
88	Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. Clinical Infectious Diseases, 2022, 74, 1686-1690.	5.8	3
89	Influenza-Associated Pulmonary Aspergillosis: Seek, and You Shall Find!. Critical Care Medicine, 2021, 49, e1265-e1266.	0.9	3
90	The Role of Genetics in Host Responses to Mucosal and Invasive Candidiasis. Current Fungal Infection Reports, 2011, 5, 262-268.	2.6	2

#	Article	IF	Citations
91	Neurosyphilis Masquerading as Herpes Encephalitis. Infectious Diseases in Clinical Practice, 2004, 12, 30-31.	0.3	1
92	Augmentation of innate host defenses against opportunistic fungal pathogens. Current Fungal Infection Reports, 2009, 3, 186-191.	2.6	1
93	Evaluation of <i>mupA</i> Evigene in Comparison to Disk Diffusion for Detection of High-Level Mupirocin Resistance in Clinical Isolates of <i>Staphylococcus aureus</i> Journal of Clinical Microbiology, 2010, 48, 2953-2954.	3.9	1
94	Invasive Candidiasis in Patients with Implants. Current Fungal Infection Reports, 2011, 5, 12-17.	2.6	1
95	Updates on the Treatment of Non-Aspergillus Hyaline Mold Infections. Current Fungal Infection Reports, 2019, 13, 308-319.	2.6	1
96	Serial Spinal Taps Prevent Complications from Elevated CSF Pressure in Cryptococcal Meningitis. Current Fungal Infection Reports, 2010, 4, 200-202.	2.6	0
97	Epidemiological and Microbiological Features of Ventricular Assist Device Associated Infections. Journal of Cardiac Failure, 2010, 16, S115.	1.7	0
98	The Growing Role of Clinical and Genomic Databases in the Development of Antifungal Strategies. Current Fungal Infection Reports, 2011, 5, 190-192.	2.6	0
99	2686. strong>Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Viridans Group Streptococcus Emerges as an Important Pathogen. Open Forum Infectious Diseases, 2019, 6, S943-S944.	0.9	0